Almac Expands Global Coverage by Adding Depots for Clinical Trial Supply Distribution to the Asia Pacific Region
Almac’s Clinical Services
have increased its presence in the Asia Pacific region. It has extended its reach by adding five new depots located in—Japan, Thailand, Hong Kong, Taiwan to its extensive global depot network. These latest developments in the Asian market enable Almac to provide customers with even more flexibility in their supply chain solution for their specific country clinical trial requirements. The number of depots within the Network is now 36 with a further five planned for 2012.
As part of Almac’s continued expansion of services globally they have also sought to expand their controlled drug network in Europe to ensure they have a network capable of storing this class of drugs within each EU country.
Almac’s Global Depot Network
is managed by dedicated depot management teams who serve as the central contact point for the network and also perform regular visits to the depots which are fully audited and GMP compliant. In line with continuous depot expansion the resources within the Depot Management Team have also increased over the past six months. There are now 15 members of staff who are located in the UK, USA, and Brazil that are dedicated to managing protocols across the depot network.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
